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Abstract 
An isocratic reversed phase stability-indicating high-performance liquid chromatographic (HPLC) assay 
method was developed and validated for quantitative determination of Meclizine HCl in bulk drugs. The developed 
method separated the drug from the degradation products, using a Water Nova Pack C18 (250 x 4.6) mm, 5μ column 
and the mobile phase containing 1.0gm Sodium dihydrogen phosphate and 1.0 gm 1-octaneSulfonic acid salt in 1000ml 
water filter and mixed. The detection was carried out at wavelength 264 nm. The developed method was validated with 
respect to linearity, accuracy (recovery), precision, system suitability, selectivity, robustness prove the stability 
indicating ability of the method. 
Keywords: HPLC, Meclizine HCl, Degradation, Chromatographic Column. 
 
1. Introduction 
Meclizine [1], is antihistamine, considered to be 
antiemetic it is used as an anti vertigo or antiemetic 
agent,-specifically in the prevention and treatment of 
nausea, vomiting and dizziness associate with motion 
sickness [2]. Meclizine works by blocking a chemical 
messenger in the brain, it helps to reduce or prevent 
vomiting and dizziness caused by motion sickness. It also 
used for vertigo caused by certain inner ear problems. 
Meclizine should be taken with caution in the elderly 
because of increased risk of confusion and amnesia [3]. 
The drug is safe in pregnancy [4]. Several methods have 
been reported for Meclizine in pharmaceutical 
preparations such as HPLC UV and capillary zone 
electrophoresis, were also developed and validated to 
detect Meclizine in pharmaceutical preparations, but the 
sensitivity is too low [5-9]. 
 
 
Molecular formula C25H27ClN2O 
Molecular weight 390.9 
IUPAC Nomenclature 1-((4-chlorophenyl)(phenyl)methyl)-4-(3-
methylbenzyl)piperazine dihydrochloride hydrate 
Colour white powder 
 
Therapeutic Category 
 
Anti-vertigo or Anti-emetic agent 
 
 
 
1.1 Literature survey 
Available literature states few HPLC methods 
for the estimation of Meclizine HCl at 254 nm. Though 
HPLC method is highly sensitive and accurate but not 
cost effective. Thus there is need to develop a simple 
rapid and economical method for routine analysis of 
Meclizine HCl. The objective of present study was to 
develop and validate simple, sensitive, accurate, precise, 
rapid and economical method for estimation of Meclizine 
HCl in bulk and in pharmaceutical formulations as per 
ICH guidelines [10, 11]. 
In continuation of our previous work, [12], 
present study involves development of RP-HPLC method 
using simple mobile phase which was sensitive and rapid 
for quantification Meclizine HCl in tablet samples as well 
as subsequent validation of developed method according 
to ICH guide lines. [13]. 
 
2. Experimental 
2.1 Material and reagents 
Meclizine HCl bulk drug was made available 
from Lupin Ltd. India (purity 99.8%). Sodium 
dihydrogen phosphate, 1- octane Sulfonic acid was 
obtained from Qualigens fine chemicals, India Limited. 
Acetonitile and methanol were obtained from Rankem 
laboratories, India. All chemicals and reagent were used 
as HPLC grades; Milli-Q-Water was used throughout the 
experiment. 
2.2 Chromatographic Conditions 
The chromatographic system (Systronic) 
consists of quaternary solvent delivery pump, a degasser, 
an auto- injector, column oven and UV detector. The 
chromatographic column of 250 mm length and internal 
diameter of 4.6 mm filled with Octadecylsilane Water 
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Nova Pack C18 (250 x 4.6) mm, 5μ stationary phase with 
particle size 5 micron and pore size 100A° was used. The 
instrumental settings were a flow of 1 ml/min, the 
injection volume was 10 μl. and wavelength 264 nm. 
2.3 Mobile Phase 
The mobile phase containing 1.0gm Sodium 
dihydrogen phosphate and 1.0 gm 1-octane Sulfonic acid 
salt in 1000ml was water filter and mixed. Prepared a 
homogenous mixture of buffer, methanol and acetonitile 
(50:20:30, v/v/v). 
2.4 Preparation of Standard stock solutions 
Standard stock solutions of 500ppm of 
Meclizine HCl in acetonitile and water (25:75) were 
prepared in volumetric flasks. 
2.5 Sample solution  
500 ppm of Meclizine HCl in 100ml calibrated 
flask containing acetonitile and water mixture 
(25:75).The desired concentration for the drug was 
obtained by accurate dilution and the analysis was 
followed up as in the general analytical procedure [14, 
15]. 
2.6 Selectivity 
Selectivity is the ability of the method to assess 
unequivocally the analyte in the presence of components, 
which may be expected to be present. Typically, these 
might include degradants, and matrix etc. The selectivity 
of the developed LC method for Meclizine HCl was 
carried out in the presence of its degradation products. 
Stress studies were performed for Meclizine HCl bulk 
drug to provide an indication of the stability indicating 
property and selectivity of the proposed method. 
Intentional degradation was attempted to stress condition 
exposing it with acid (0.25 N Hydrochloric acid), alkali 
(0.25N NaOH) hydrogen peroxide (10%) heat (60°C) to 
evaluate the ability of the proposed method to separate 
Meclizine HCl from its degraded products. For heat, 
study period was 3 days, for acid, oxidation it was 48 hr, 
and for base 2 hour. Assay studies were carried out for 
stress samples against Meclizine HCl reference standard 
and the mass balance (% assay + % sum of all impurities 
+ % sum of all degraded products) was calculated. 
 
3. Results and discussion 
3.1 Optimization of chromatographic conditions 
The main target for the development of 
chromatographic method was to get the reliable method 
for the quantification of Meclizine HCl from bulk drug 
and which will be also applicable for the degradable 
products. Initially, we took the effort for the development 
of HPLC method quantification of standard Meclizine 
HCl from bulk. Satisfactory results were obtained when 
used, Water nova pack C18 (250mm x 4.6) mm, 5µ gave 
the graph with better Gaussian. For optimization of this 
method various solvents-buffer combination have been 
tried such as 0.1M KH2PO4 and Acetonitile (60:40,v/v), 
0.01M Ammonium acetate pH-5.9 and acetonitile 
(20:80,v/v), Acetonitile and water (80:20, v/v), K2HPO4, 
Methanol and water (10:70:20,v/v/v), 1.0gm KH2PO4 and 
0.45gm 1-Hexa sulphonic acid sodium salt and Ortho 
phosphoric acid with methanol (25:75, v/v) all these 
combination were not satisfactory. The solvent buffer 
combination for quantification of Meclizine HCl was 
found with 2.0gm Sodium dihydrogen phosphate and 1.0 
gm 1-octaneSulfonic acid salt in 1000ml water filter and 
mixed. 
3.2 Method Validation 
The validation of analytical procedures is based 
on the four most common types of analytical procedures: 
Identification tests, Quantitative tests for impurities' 
content, Limit tests for the control of impurities, 
Quantitative tests of the active moiety in samples of drug 
substance or drug product or other selected component in 
the drug product. 
In the present study the developed method was validated, 
as described below, for various parameters like linearity 
and range, accuracy, precision, ruggedness, system 
suitability, specificity, LOQ, and LOD. 
3.3 System suitability 
For system suitability studies, five replicate 
injections of acid, base and oxidative degraded solutions 
were used and the RSD of peak area ratio, resolutions, 
tailing factor and number of theoretical plates of the peak 
were calculated. The system suitability results are shown 
in Table 1. 
Table 1: System stability study 
Working Standard Wt. of Standard (mg) Area 
Injection-1 25.29 mg 11885.60 
Injection-2 ------ 11890.10 
Injection-3 ------ 11876.50 
Injection-4 ------ 11882.40 
Injection-5 ------ 11868.70 
Injection-6 ------ 11876.00 
AVG ------ 11879.88 
SD ------ 7.68 
%RSD ------ 0.06 
 
3.4 Precision 
The precision of the method was studied by 
determining the concentrations of the drug Meclizine HCl 
in the tablet for six times. The results of the precision 
study (Table 3) indicate the reliability of the method 
(RSD %< 2). 
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Table 2: Results of system precision as is basis 
Sample No. Wt. of sample (mg) Area Assay (as is basis) Assay (on dried basis) 
1 25.06 11648.80 95.65 99.54 
2 25.01 11620.80 95.61 99.50 
3 24.95 11589.40 95.58 99.47 
4 25.08 11662.60 95.69 99.58 
5 25.75 11968.60 95.64 99.53 
6 24.96 11593.00 95.57 99.46 
AVG ---- ---- 95.62 99.51 
SD ---- ---- 0.04 0.05 
%RSD ---- ---- 0.05 0.05 
 
Table 3: Results of Intermediate system precision (Standard) 
Working Standard  Wt. of Standard (mg)  Retention time Area 
Injection-1 25.01 10.61 10500154.00 
Injection-2 25.01 10.61 10509628.00 
Injection-3 25.01 10.60 10500217.00 
Injection-4 25.01 10.60 10500103.00 
Injection-5 25.01 10.61 10509909.00 
Injection-6 25.01 10.61 10511842.00 
AVG 25.01 10.61 10505308.83 
SD 25.01 0.01 5693.83 
%RSD 25.01 0.05 0.05 
 
Table 4: Results of Intermediate system precision (Sample) 
Sample No. Wt. of sample 
(mg) 
 Area Assay (as such 
basis) 
Assay (on dried 
basis) 
1 25.27 10.61 10509774.00 95.71 99.60 
2 25.31 10.61 10511791.00 95.57 99.46 
3 25.22 10.61 10490796.00 95.72 99.62 
4 25.18 10.61 10470694.00 95.69 99.58 
5 25.18 10.60 10468665.00 95.67 99.57 
6 25.17 10.60 10453450.00 95.57 99.46 
AVG ---- 10.61 ---- 95.66 99.55 
SD ---- 0.01 ---- 0.07 0.07 
%RSD ---- 0.05 ---- 0.07 0.07 
 
Figure 1: A typical chromatogram of Meclizine HCl Standard 
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Figure 2: A typical chromatogram of Meclizine HCl Sample 
3.5 Accuracy (Recovery test) 
The accuracy of an analytical procedure 
expresses the closeness of agreement between the value, 
which is accepted either as a conventional true value or 
an accepted reference value and the value found. This is 
sometimes termed trueness.[19, 20] 
Accuracy, sometimes also referred to as 
recovery is an indicator of the trueness of the test 
measurements.[20] To determine the accuracy of the 
method three quality control samples were used. The 
samples chosen were such to represent the entire range of 
the standard curve i.e. lower, middle and higher 
concentration of the range.[21] 
The recovery experiments were carried out by the 
standard addition method. The recoveries obtained by the 
RP-HPLC method for Meclizine HCl are depicted in 
Table 5. 
 
Table 5: Results of the recovery tests for the Meclizine HCl 
Level of Addition (%) Amount added (n=3) ppm % Recovery * % Average recovery† 
80 50 98.11 98.14 
100 100 99.22 99.44 
120 150 99.70 99.65 
 
3.6 Calibration and linearity 
Linearity test solutions for the method were 
prepared from Meclizine HCl stock solutions at six 
concentrations levels from tested from 80% to 120% of 
the targeted level of the assay concentration Meclizine 
HCl. Standard solutions containing 80-120 μg/ml of 
Meclizine HCl in each linearity level were prepared. 
Linearity solutions were injected in triplicate. The 
calibration graphs were obtained by plotting peak area 
verses the concentration data was treated by least-squares 
linear regression analysis, the calibration graphs were 
found to be linear in the mentioned concentrations the 
slopes and correlation coefficients are shown in Table 6. 
The standard curve found to be linear over the 
concentration range of 125-375 ppm. The equation of the 
standard curve relating the peak area to the Meclizine 
hydrochloride concentration in this range was y = 42.48x 
+ 170.9. The present study reveals that, the drug showed 
good linearity in the range of 125-375 ppm with 
coefficient of correlation value 0.9999 for peak area. 
Table 6: Results of the LOD and LOQ 
Name % LOD %LOQ 
Meclizine HCl 0.11 0.43 
 
Figure 2: Linearity graph of Meclizine HCl 
 
 
3.7 Robustness 
To determine the robustness of the developed 
method experimental condition were purposely altered 
and the resolution between Meclizine HCl and acid 
degraded product were evaluated. The flow rate of the 
mobile phase was 1.0 ml/min. To study the effect of flow 
rate on the resolution, it was changed by 0.2 units from 
0.8 to 1.2ml/min while the other mobile phase component 
was held as stated in chromatographic conditions. The 
effect of percent organic strength on resolution was 
studied by varying acetonitrile from –10 to +10 % while 
other mobile phase components were held constant as 
stated in chromatographic condition. The effect of 
column temperature on resolution was studied at 25 and 
35
o
C instead of 30
o
C while the other mobile phase 
components were held constant stated in chromatographic 
condition. The results are shown in Table-6 
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Table 6: Results of robustness study 
Sr.No. Parameters Standard parameter Changes studied 
1 Flow rate 1.4 ml/min. 1.3 ml/min. 1.5 ml/min. 
2 pH of Phosphate 
buffer 
6.50 6.40 6.60 
3 Mobile phase 
composition 
Water : ACN : 
Phosphate buffer: Sulphate 
buffer250 : 750 : 50 :50 
Water : ACN :Phosphate 
buffer :Sulphate buffer 
230 : 770 : 50 : 50 
Water : ACN :Phosphate 
buffer :Sulphate buffer 
270 : 730 : 50 :50 
 
3.8 LOD and LOQ (Sensitivity) 
A series of solutions in the range 0.2–1.1% of 
the assay concentration (40 μg mL−1) were prepared by 
dilution of the standard solutions. Each solution (20 μL) 
was injected five times, the areas were measured for the 
drug peak, and the standard deviation for the five 
injections was calculated for each concentration. On the 
basis of data obtained, the standard deviation at 
concentration 0 was calculated and this value was used 
for calculation of the LOD and LOQ.  
3.9 Stability of analytical solution 
The stability of the standard solutions and the 
sample solutions was tested at intervals of 24, 48 and 72 
h. The stability of solutions was determined by 
comparing results of the assay of the freshly prepared 
standard solutions. The RSD for the assay results 
determined up to 72 h for Meclizine HCl was 0.35 %. 
The assay values were within + 2 % after 72 h. The 
results indicate that the solutions were stable for 72 h at 
ambient temperature. 
 
4. Conclusion 
The method developed for quantitative 
determination of Meclizine HCl is rapid, precise, accurate 
and selective. The method was completely validated 
showing satisfactory data for all method-validated 
parameters tested. The developed method is stability 
indicating and can be used for assessing the stability of 
Meclizine HCl as bulk drugs. The developed method can 
be conveniently used for the assay determination of 
Meclizine HCl in bulk drugs and pharmaceutical dosage 
form. 
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